309 related articles for article (PubMed ID: 27641974)
1. Risk of Intussusception with Rotavirus Vaccine.
Kalaiselvan V; Thota P; Kumar V; Rathore MS; Thota A; Singh GN
Indian J Pediatr; 2017 Feb; 84(2):97-100. PubMed ID: 27641974
[TBL] [Abstract][Full Text] [Related]
2. Rotavirus Vaccination in India - Need for Surveillance of Intussusception.
Dutta AK
Indian J Pediatr; 2017 Feb; 84(2):95-96. PubMed ID: 27796816
[No Abstract] [Full Text] [Related]
3. An analysis of rotavirus vaccine reports to the vaccine adverse event reporting system: more than intussusception alone?
Haber P; Chen RT; Zanardi LR; Mootrey GT; English R; Braun MM;
Pediatrics; 2004 Apr; 113(4):e353-9. PubMed ID: 15060267
[TBL] [Abstract][Full Text] [Related]
4. [Post-licensure passive safety surveillance of rotavirus vaccines: reporting sensitivity for intussusception].
Pérez-Vilar S; Díez-Domingo J; Gomar-Fayos J; Pastor-Villalba E; Sastre-Cantón M; Puig-Barberà J
An Pediatr (Barc); 2014 Aug; 81(2):77-85. PubMed ID: 24252603
[TBL] [Abstract][Full Text] [Related]
5. Review of Over 15 Years Postmarketing Safety Surveillance Spontaneous Data for the Human Rotavirus Vaccine (Rotarix) on Intussusception.
Singh T; Delannois F; Haguinet F; Molo LY
Drug Saf; 2022 Feb; 45(2):155-168. PubMed ID: 35015268
[TBL] [Abstract][Full Text] [Related]
6. Retrospective hospital based surveillance of intussusception in children in a sentinel paediatric hospital: benefits and pitfalls for use in post-marketing surveillance of rotavirus vaccines.
Lloyd-Johnsen C; Justice F; Donath S; Bines JE
Vaccine; 2012 Apr; 30 Suppl 1():A190-5. PubMed ID: 22520131
[TBL] [Abstract][Full Text] [Related]
7. Intussusception among recipients of rotavirus vaccine: reports to the vaccine adverse event reporting system.
Zanardi LR; Haber P; Mootrey GT; Niu MT; Wharton M
Pediatrics; 2001 Jun; 107(6):E97. PubMed ID: 11389295
[TBL] [Abstract][Full Text] [Related]
8. Intussusception risk after RotaTeq vaccination: evaluation from worldwide spontaneous reporting data using a self-controlled case series approach.
Escolano S; Hill C; Tubert-Bitter P
Vaccine; 2015 Feb; 33(8):1017-20. PubMed ID: 25596460
[TBL] [Abstract][Full Text] [Related]
9. Safety monitoring of ROTAVAC vaccine and etiological investigation of intussusception in India: study protocol.
Reddy S; Nair NP; Giri S; Mohan VR; Tate JE; Parashar UD; Gupte MD; Arora R; Kang G;
BMC Public Health; 2018 Jul; 18(1):898. PubMed ID: 30029630
[TBL] [Abstract][Full Text] [Related]
10. Safety profile of rotavirus vaccines among individuals aged ≥8 months of age, United States, vaccine adverse event reporting system (VAERS), 2006-2019.
Haber P; Tate J; Marquez PL; Moro PL; Parashar U
Vaccine; 2021 Jan; 39(4):746-750. PubMed ID: 33267969
[TBL] [Abstract][Full Text] [Related]
11. Potential intussusception risk versus health benefits from rotavirus vaccination in Latin America.
Desai R; Parashar UD; Lopman B; de Oliveira LH; Clark AD; Sanderson CF; Tate JE; Matus CR; Andrus JK; Patel MM
Clin Infect Dis; 2012 May; 54(10):1397-405. PubMed ID: 22431803
[TBL] [Abstract][Full Text] [Related]
12. Risk of intussusception after monovalent rotavirus vaccine (Rotavac) in Indian infants: A self-controlled case series analysis.
INCLEN Intussusception Surveillance Network Study Group
Vaccine; 2021 Jan; 39(1):78-84. PubMed ID: 32972735
[TBL] [Abstract][Full Text] [Related]
13. Rotavirus vaccines and intussusception risk.
Bines JE
Curr Opin Gastroenterol; 2005 Jan; 21(1):20-5. PubMed ID: 15687880
[TBL] [Abstract][Full Text] [Related]
14. Intussusception after rotavirus vaccines reported to US VAERS, 2006-2012.
Haber P; Patel M; Pan Y; Baggs J; Haber M; Museru O; Yue X; Lewis P; Destefano F; Parashar UD
Pediatrics; 2013 Jun; 131(6):1042-9. PubMed ID: 23669521
[TBL] [Abstract][Full Text] [Related]
15. Research priorities regarding rotavirus vaccine and intussusception: a meeting summary.
Tate JE; Steele AD; Bines JE; Zuber PL; Parashar UD
Vaccine; 2012 Apr; 30 Suppl 1():A179-84. PubMed ID: 22520129
[TBL] [Abstract][Full Text] [Related]
16. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya, including among HIV-infected and HIV-exposed infants.
Laserson KF; Nyakundi D; Feikin DR; Nyambane G; Cook E; Oyieko J; Ojwando J; Rivers SB; Ciarlet M; Neuzil KM; Breiman RF
Vaccine; 2012 Apr; 30 Suppl 1():A61-70. PubMed ID: 22520138
[TBL] [Abstract][Full Text] [Related]
17. Broadening the age restriction for initiating rotavirus vaccination in regions with high rotavirus mortality: benefits of mortality reduction versus risk of fatal intussusception.
Patel MM; Clark AD; Glass RI; Greenberg H; Tate J; Santosham M; Sanderson CF; Steele D; Cortese M; Parashar UD
Vaccine; 2009 May; 27(22):2916-22. PubMed ID: 19428901
[TBL] [Abstract][Full Text] [Related]
18. Approaches to monitoring intussusception following rotavirus vaccination.
Tate JE; Parashar UD
Expert Opin Drug Saf; 2019 Jan; 18(1):21-27. PubMed ID: 30570424
[TBL] [Abstract][Full Text] [Related]
19. Workshop on intussusception in African countries--meeting report.
Steele AD; Patel M; Cunliffe NA; Bresee JS; Borgstein E; Parashar UD
Vaccine; 2012 Apr; 30 Suppl 1():A185-9. PubMed ID: 22520130
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of using regional sentinel surveillance to monitor the rotavirus vaccine impact, effectiveness and intussusception incidence in the African Region.
Mandomando I; Weldegebriel G; de Deus N; Mwenda JM
Vaccine; 2017 Mar; 35(13):1663-1667. PubMed ID: 28242070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
